Story perspectives

OpenAI Unveils GPT-Rosalind to Transform Drug Discovery

4/17/2026

Summary

Story summary

OpenAI launched GPT-Rosalind to accelerate drug discovery and life sciences research.
The model is named after Rosalind Franklin and helps synthesize evidence, generate hypotheses, and plan experiments.
Initial users include Amgen, Moderna, and the Allen Institute, and the model integrates with existing tools and databases.
OpenAI maintains safety through a Trusted Access program to prevent misuse.
Early tests show promising results, positioning GPT-Rosalind as a significant advancement.

1 of 1

Story summary

OpenAI launched GPT-Rosalind to accelerate drug discovery and life sciences research.
The model is named after Rosalind Franklin and helps synthesize evidence, generate hypotheses, and plan experiments.
Initial users include Amgen, Moderna, and the Allen Institute, and the model integrates with existing tools and databases.
OpenAI maintains safety through a Trusted Access program to prevent misuse.
Early tests show promising results, positioning GPT-Rosalind as a significant advancement.